Abstract:Abstract Introduction: Occupational exposure to arylamine compounds is a well-established risk factor for bladder cancer. With greater regulation, industrial arylamine exposure in the United States has reduced, thus making tobacco smoke the predominant source of arylamine exposure. Though exposure is greater in China than in the US, bladder cancer rates are higher in the US. These circumstances, together with evidence of familial aggregation of bladder cancer, have long suggested a role of inherited genetic factors in disease etiology. Previous studies indicate that slow variants of polymorphic N-acetyltranseferase, an arylamine-metabolizing enzyme encoded by the NAT2 locus, is a risk factor. Differences in distribution of slow acetylation may underlie demonstrated ethnic differences in bladder cancer risk. Thus cases of transitional cell carcinoma of the urinary bladder were studied to understand the role of the NAT2 gene and arylamine exposure differences between Caucasians and Chinese. Methods: A population-based case-control study of bladder cancer conducted in Los Angeles County (LA), California and Shanghai, China. Cases were diagnosed with urothelial carcinoma from 1987 to 1996 and from 1995 to 1998 in Shanghai. Controls were matched on gender, age in both populations, with further matching on neighborhood in Los Angeles. Participants completed in-person interviews providing information on several risk factors including smoking. All Shanghai participants and those LA participants interviewed from 1992 onward provided peripheral blood samples. Participants also provided samples of urine following timed ingestion of caffeine from which urinary metabolite ratios were assessed as a phenotypic measure of NAT2 activity. Genotypic analysis of 30 Tag SNPs within the NAT2 locus was conducted, and inferred phenotype assigned by haplotype analysis (SAS/Genetics, Proc Haplotype) followed by assignment of “slow” and “rapid” alleles according to consensus NAT2 gene nomenclature (http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-acetyltransferase-gene-nomenclature/nat_pdf_files/Human_NAT2_alleles.pdf) was done. Gene-disease associations were estimated in subsequent statistical analysis employing logistic regression using N:M matching and an additive model for genetic effect. Results: 786 (LA) and 1026 (Shanghai) participants contributed to the analysis. As previously reported (Carcinogenesis 29:1386, 2008), bladder cancer risk was associated with “slow” measured phenotype among the LA participants who reported smoking 30 or more pack-years. Among LA participants, we further observed that rs1495741A (OR=1.47, 95% CI: 1.08–1.99) to be associated with risk, as reported for a separate study population of European origin (Pharmacogenetics and Genomics 21:231,2011). Among Shanghai participants, “slow” measured phenotype was also associated with risk (OR=1.44, 95% CI: 1.08–1.92). Unexpectedly, among Shanghai participants, both the “slow” inferred phenotype and rs1495741A allele were associated with risk in the direction opposite to that observed among LA participants (OR=0.65, 95% CI: 0.44–0.94; OR=0.70, 95% CI: 0.50–0.97). Based upon consensus NAT2 gene nomenclature, nearly 29% of Shanghai participants had at least one haplotype defined as a “slow substrate dependent” allele, whereas such alleles were observed in fewer than 3% of LA participants. Conclusions: Lower bladder cancer occurrence among Chinese compared with non-Hispanic whites may be related in part to differences in genetic susceptibility. Additional studies are ongoing to clarify whether ethnic differences in associations to inferred phenotype and to rs1495741A arise from differences in organization of the NAT2 locus between populations of European and Chinese descent as well as differential exposure of these populations to mono-versus diarylamines (Int J Cancer 118:161, 2006), or perhaps to both of these factors. Citation Information: Cancer Prev Res 2011;4(10 Suppl):A62.

Abstract C167: Understanding the effect of single nucleotide polymorphism rs2292596 on the interaction of aryl hydrocarbon receptor repressor and aryl hydrocarbon receptor nuclear translocator

Nucleotide Excision Repair Gene ERCC1 19007T>C Polymorphism Contributes to Lung Cancer Susceptibility: A Meta-Analysis

Abstract 4595: the Impact of CYP2A6 Genetic Polymorphisms on Nicotine Metabolism and Lung Cancer Risk in Two Prospective Cohorts of Smokers

Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5.

Abstract 4149: Genetic Variation in CYP2A6, a Nicotine/nitrosamine Metabolism Enzyme, Influences Lung Cancer Risk in Two Independent Case-Control Studies of African American Smokers

Abstract 1948: Novel insights into lung cancer & chronic obstructive pulmonary disease racial disparities

Association of Human Aryl Hydrocarbon Receptor Gene Polymorphisms with Risk of Lung Cancer among Cigarette Smokers in a Chinese Population

Abstract 937: Nicotinic acetylcholine receptor polymorphisms, secondhand smoke and lung cancer risk

Abstract 4830: Predicting drug treatment response in African American lung cancer patients who smoke

Abstract C171: Identifying cancer driver mutation signatures in lung adenocarcinoma from Black/African American individuals: Addressing cancer health disparities

Meta-analysis of the CYP1A2 -163C>A Polymorphism and Lung Cancer Risk.

Beta-2 adrenergic receptor gene (ADRB2) polymorphism and risk for lung adenocarcinoma: a case-control study in a Chinese population.

Abstract PR001: A comparison of modeling approaches to assess the interplay of social, behavioral, and environmental factors on lung cancer racial disparities

Abstract A62: Tobacco Exposure, Risk for Bladder Cancer, and Modification by NAT2 in Different Ethnic Populations

Apoptosis gene polymorphisms and the risk of non-small cell lung cancer

Abstract 7327: Investigating the cell-type specific regulation of IRF4 and its role in lung cancer via a lung cancer risk-associated pleiotropic variant

Substantial Reduction in Risk of Lung Adenocarcinoma Associated with Genetic Polymorphism in CYP2A13, the Most Active Cytochrome P450 for the Metabolic Activation of Tobacco-Specific Carcinogen NNK.

XRCC3 Genetic Polymorphism, Smoking, and Lung Carcinoma Risk in Minority Populations

Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk.

Class A Scavenger Receptor Deficiency Exacerbates Lung Tumorigenesis by Cultivating a Procarcinogenic Microenvironment in Humans and Mice.

Association Between ADRB2, IL33, and IL2RB Gene Polymorphisms and Lung Cancer Risk in a Chinese Han Population.